| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement to Referees
|
|
|
|
19 |
6 |
p. 819-822
|
artikel
|
| 2 |
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
|
Hamilton, Erika P.
|
|
|
19 |
6 |
p. 879-892
|
artikel
|
| 3 |
Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics
|
Wu, Lawrence W.
|
|
|
19 |
6 |
p. 845-865
|
artikel
|
| 4 |
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
|
Fiala, Ondřej
|
|
|
19 |
6 |
p. 905-915
|
artikel
|
| 5 |
Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
|
Willemin, Marie-Emilie
|
|
|
19 |
6 |
p. 965-979
|
artikel
|
| 6 |
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific
|
Kim, Sejin
|
|
|
19 |
6 |
p. 917-923
|
artikel
|
| 7 |
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01
|
Hibino, Makoto
|
|
|
19 |
6 |
p. 925-939
|
artikel
|
| 8 |
Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
|
Koseki, Mako
|
|
|
19 |
6 |
p. 867-877
|
artikel
|
| 9 |
Physician Perspectives on the Management of Patients with Resected High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Who Are Ineligible to Receive Cisplatin: A Podcast
|
Haddad, Robert I.
|
|
|
19 |
6 |
p. 823-832
|
artikel
|
| 10 |
Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial
|
Yılmaz, Feride
|
|
|
19 |
6 |
p. 957-964
|
artikel
|
| 11 |
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
|
Santini, Daniele
|
|
|
19 |
6 |
p. 893-903
|
artikel
|
| 12 |
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study
|
Basin, Michael F.
|
|
|
19 |
6 |
p. 981-990
|
artikel
|
| 13 |
Taiwan Nationwide Study of First-Line ALK–TKI Therapy in ALK-Positive Lung Adenocarcinoma
|
Zheng, Zhe-Rong
|
|
|
19 |
6 |
p. 941-955
|
artikel
|
| 14 |
The Epidemiology of Biliary Tract Cancer and Associated Prevalence of MDM2 Amplification: A Targeted Literature Review
|
Kratz, Jeremy David
|
|
|
19 |
6 |
p. 833-844
|
artikel
|
Tijdschrift beschrijving